Anzeige
Meldung des Tages: Europas Energie-Vorteil: Während Miner kämpfen: In Finnland entsteht der vielleicht billigste Bitcoin Europas

OKYO PHARMA LTD News

Aktie
WKN:  A2JQ3D ISIN:  GG00BD3FV870 US-Symbol:  EMMLF
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
68,08%
KGV
-
Index-Zuordnung
-

OKYO PHARMA LTD News

29.10.25 - GlobeNewswire
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
LONDON and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
16.10.25 - GlobeNewswire
OKYO Pharma Announces Chairman and Founder Acquires Shares
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:  OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
22.09.25 - GlobeNewswire
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
17.07.25 - GlobeNewswire
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-​focused bio-​pharmaceutical company which is ...
16.07.25 - GlobeNewswire
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-​protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual ...
11.06.25 - GlobeNewswire
OKYO Pharma to Present at the Bio International Convention
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-​stage biopharmaceutical company developing innovative ...
19.05.25 - GlobeNewswire
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-​stage biopharmaceutical company developing innovative ...
01.05.25 - GlobeNewswire
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-​focused bio-​pharmaceutical company which is ...
30.04.25 - GlobeNewswire
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-​masked, randomized, 12-week placebo-...

Newssuche

Videos

newspaper
20.04.26 +4,31%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »